688026 Guangzhou Jet Bio-Filtration
- 10.24
- -0.22-2.10%
Guangzhou Jet Bio-Filtration News
Jet Biotech (688026): Continued improvement in performance, optimistic about increasing the medium- to long-term localization rate
The incident described that in 2023, the company achieved operating income of 463 million yuan, a year-on-year decrease of 24.06%, and net profit to mother of 347.885 million yuan, a year-on-year decrease of 60.34%. Company revenue for the first quarter of 2024 98
Jiete Biotech (688026.SH) appoints Xie Feng as the company's financial director
Jet Biotech (688026.SH) announced that the board of directors of the company reviewed and approved the relevant resolution on May 22, 2024...
Jiete Biotech (688026.SH) spent a total of 20065,500 yuan to buy back 1.22% of the company's shares
Jet Biotech (688026.SH) issued an announcement. As of the announcement disclosure date, the company traded through the Shanghai Stock Exchange...
Jet Biotech (688026): Short-term pressure on performance is expected to resume growth in 2024
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 463 million yuan (yoy -24.06%) and net profit of 35 million yuan (yoy-60)
Jiete Biotech (688026.SH): 1.22% of the company's shares have been repurchased
Gelonghui, May 6 | Jet Biotech (688026.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,708,861 shares of the company through centralized bidding transactions, accounting for 1.22% of the company's total share capital of 140,363,220 shares. The highest price of the repurchase transaction was 13.13 yuan/share, the lowest price was 11.15 yuan/share, and the total amount of capital paid was RMB 20,065,542.30 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Jiete Biotech: The company's consumables can be used in the field of synthetic biology
Jet Convertible Bonds: Expected to meet the conversion price correction conditions
Guangzhou Jet Biofiltration Co., Ltd. announced that from April 16, 2024 to April 29, 2024, the closing price of the company's stock was lower than 85% of the current share conversion price for 10 trading days, which is expected to trigger downward revision conditions for the “Jet Bonds” conversion price.
Jiete Biotech (688026.SH) reported first-quarter results, net profit of 8.178,500 yuan, an increase of 192.97% over the previous year
Jet Biotech (688026.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Guohai Securities released a research report on April 23 stating that it gave Jiete Biotech (688026.SH) a purchase rating. The main reasons for the rating include: 1) slow recovery in overseas market demand and declining company performance; 2) actively p
Guohai Securities released a research report on April 23 stating that it gave Jiete Biotech (688026.SH) a purchase rating. The main reasons for the rating include: 1) slow recovery in overseas market demand and declining company performance; 2) actively promoting the implementation of fund-raising projects and continuing to improve core technology; 3) improving independent brand building and extending the layout of medical supplies and equipment. (Mainichi Keizai Shimbun)
Jet Biotech (688026) 2023 Annual Report Review Report: Fundraising Projects Promote Independent Brands in an Orderly Way to Accelerate Upgrading
Event: On April 20, 2024, Jet Biotech released its 2023 annual report: achieved operating income of 463 million yuan in 2023, a year-on-year decrease of 24.06%; realized net profit of 35 million yuan to mother.
Zhongtai Securities released a research report on April 22 stating that it will maintain the purchase rating of Jiete Biotech (688026.SH). The main reasons for the rating include: 1) the company released its 2023 annual report, and the company achieved re
Zhongtai Securities released a research report on April 22 stating that it will maintain the purchase rating of Jiete Biotech (688026.SH). The main reasons for the rating include: 1) the company released its 2023 annual report, and the company achieved revenue in 2023; 2) factors such as reduced revenue and increased depreciation investment affected short-term profit margins; 3) performance declined due to adverse effects such as geopolitics, inventory digestion, and production capacity clearance, which is expected to usher in healthy growth in 2024; 4) the gradual implementation of intelligent manufacturing projects and the accelerated expansion of domestic and foreign markets. (Mainichi Keizai Shimbun)
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
Jiete Biotech (688026): Demand for conventional scientific research consumables stabilizes and is expected to gradually recover in 2024
Incident: The company released its 2023 annual report. In 2023, the company achieved operating income of 463 million yuan, a year-on-year decrease of 24.06%, and net profit to mother of 34.79 million yuan, a year-on-year decrease of 60.34%, minus non-net profit 31
Jet Biotech (688026.SH): Net profit in 2023 fell 60.34% year-on-year, and plans to pay 10 to 0.722 yuan
On April 19, Ge Longhui (688026.SH) announced its 2023 annual report. During the reporting period, it achieved operating income of 463 million yuan, a year-on-year decrease of 24.06%; net profit attributable to shareholders of listed companies was 347.885 million yuan, a year-on-year decrease of 60.34%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 31.7846 million yuan, a year-on-year decrease of 57.90%; and basic earnings per share were 0.25 yuan. The company plans to distribute a cash dividend of RMB 0.722 (tax included) to all shareholders for every 10 shares.
Express News | New national standard for cell culture residue testing developed with the participation of Jet Biotech released
Jiete Biotech (688026.SH): Has repurchased a total of 1,708,900 shares
Gelonghui, April 1 | Jet Biotech (688026.SH) announced that as of March 31, 2024, the company had repurchased 1,708,900 shares of the company's shares through centralized bidding transactions, accounting for 1.22% of the company's total share capital of 140,363,220 shares. The highest price of the repurchase transaction was 13.13 yuan/share, the lowest price was 11.15 yuan/share, and the total amount of capital paid was RMB 20,065,542.30 (excluding transaction fees such as stamp duty and transaction fees).
Jiete Biotech (688026.SH): A total cost of 167.656 million yuan to buy back 1.01% of the shares
Gelonghui, March 5, 丨 Jet Biotech (688026.SH) announced that as of March 5, 2024, the company had repurchased 1,418,633 shares of the company through centralized bidding transactions, accounting for 1.01% of the company's total share capital of 140,363,220 shares, an increase of 0.49% compared with the previous disclosure. The highest price of the repurchase transaction was RMB 13.13 per share, and the lowest price was RMB 11.17 per share, and the total amount of capital paid was RMB 16,765,562.66.
Jiete Biotech (688026.SH): A total of 0.52% shares have been repurchased
Gelonghui, Feb. 29丨Jet Biotech (688026.SH) announced that as of February 29, 2024, the company had repurchased a total of 725,787 shares of the company through centralized bidding transactions, accounting for 0.52% of the company's total share capital. The highest price of the repurchase transaction was 13.13 yuan/share, the lowest price was 11.17 yuan/share, and the total amount of capital paid was RMB 8,765,681.50 (excluding transaction fees such as stamp duty and transaction commissions).
Jet Biotech (688026.SH): 0.16% share repurchase for the first time
Gelonghui, Feb. 27丨Jet Biotech (688026.SH) announced that on February 27, 2024, the company repurchased 219,781 shares for the first time through the Shanghai Stock Exchange system, accounting for 0.16% of the company's total share capital of 140,363,220 shares. The highest price of the repurchase transaction was 12.69 yuan/share, the lowest price was 12.53 yuan/share, and the total amount of capital paid was RMB 2,765,726.90.
Yuan Jianhua, one of the actual controllers of Jiete Biotech (688026.SH), increased his holdings by 309,000 shares
Jet Biotech (688026.SH) announced that Mr. Yuan Jianhua, the controlling shareholder, one of the actual controllers and chairman of the company...
Analysis
Price Target
No Data
